ArticleAnnals of neurology2024
Proteomic Indicators of Health Predict Alzheimer's Disease Biomarker Levels and Dementia Risk.
Article in Annals of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Neuroinflammatory fluid biomarkers in patients with Alzheimer's disease: a systematic literature review.Molecular psychiatry · 2025Pooled it
- Associations of amyloid biomarkers with brain and cognitive changes from imaging, spinal fluid, and plasma.medRxiv : the preprint server for health sciences · 2026Article
- Plasma Biomarkers, Brain Volume, and Cognitive Performance in Service Members and Veterans With mTBI: A LIMBIC-CENC Study.JAMA network open · 2026Article
- Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome. Insights from a comprehensive mechanistic quantitative systems pharmacology study.Frontiers in pharmacology · 2026Article
- Plasma chaperone-mediated autophagy associated protein HSPA8 combined with white matter hyperintensities serves as the predictive marker of early-stage Alzheimer's disease.Frontiers in aging neuroscience · 2026Article
- Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.Journal of clinical pharmacology · 2025Article
- The relationship between kidney health and neurodegenerative diseases.Brain : a journal of neurology · 2025Review
- SomaScan Bioinformatics: Normalization, Quality Control, and Assessment of Pre-Analytical Variation.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Is the Relationship Between Cardiovascular Disease and Alzheimer's Disease Genetic? A Scoping Review.Genes · 2024Article
- Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer's disease.Acta neuropathologica · 2024Article
- Caregiving-Related Depression Increases Neuroinflammation in Spousal Caregivers to Individuals With Cognitive Impairment: A Longitudinal Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Association of Plasma Markers of Alzheimer's Disease, Neurodegeneration, and Neuroinflammation with the Choroid Plexus Integrity in Aging.Aging and disease · 2024Article
- Integrating amyloid and tau imaging with proteomics and genomics in Alzheimer's disease.Cell reports. Medicine · 2024Review
- Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.Alzheimer's research & therapy · 2024Article
- Plasma biomarkers for Alzheimer's and related dementias: A review and outlook for clinical neuropsychology.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 8 institutions in 1 country.
Funding
Abstract
objectiveFew studies have comprehensively examined how health and disease risk influence Alzheimer's disease (AD) biomarkers. The present study examined the association of 14 protein-based health indicators with plasma and neuroimaging biomarkers of AD and neurodegeneration.
methodsIn 706 cognitively normal adults, we examined whether 14 protein-based health indices (ie, SomaSignal® tests) were associated with concurrently measured plasma-based biomarkers of AD pathology (amyloid-β [Aβ]
resultsGreater protein-based risk for cardiovascular disease, heart failure mortality, and kidney disease was associated with lower Aβ
interpretationSubclinical peripheral health may influence AD and neurodegenerative disease processes and relevant biomarker levels, particularly NfL. Cardiovascular health, even in the absence of clinically defined disease, plays a central role in brain aging and dementia. ANN NEUROL 2024;95:260-273.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.